Glaxosmithkline Regulatory News (GSK)

Issued: 25 November 2022, London UK - LSE Announcement

Publication of Final Terms

GSK Capital B.V. announces that the following final terms dated 25 November 2022 (the "Final Terms") in respect of the Notes (as defined below) are available for viewing:

GSK Capital B.V. issue of:

EUR 500,000,000 3.000% Notes due 2027; and

EUR 750,000,000 3.125% Notes due 2032.

in each case guaranteed by GSK plc issued under the £20,000,000,000 Euro Medium Term Note Programme (the "Notes")

Copies of the Final Terms have been submitted to the Financial Conduct Authority's NSM submission portal via the Electronic Submission System (ESS). A copy can be viewed at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information, please contact:

GSK plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited Kingdom

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND PROSPECTUS

Please note that the information contained in the Final Terms and the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.